Year-end Sale % OFF 
Abstract
Over the last 15 years, we have seen a rapid and exponential uptake of transcatheter aortic valve implantation (TAVI) for the treatment of patients with severe symptomatic aortic stenosis (1). This uptake has also been coupled with the evolution and advancement in transcatheter valve technologies. As such, a number of new TAVI devices have also been marketed, mainly with the aim of diminishing problems faced with first generation devices; notably, smaller delivery systems, less incidence of paravalvular leak (PVL) or need for permanent pacemaker implantation (PPI) and other device- or procedural related complications (2,3).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
